Maurilio Sampaolesi

Prof. Maurilio Sampaolesi

Development and regeneration, KU Leuven, Leuven, Belgium
orcid

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2005 in Cancer Cell
Verified
Journal Article
Closed access
MPMichele De Palma
Michele De Palma
MARY ANNA VENNERIMARY ANNA VENNERI
MARY ANNA VENNERI
RGRossella Galli
Rossella Galli
LSLucia Sergi Sergi
Lucia Sergi Sergi
LPLetterio S. Politi
Letterio S. Politi
LNLuigi Naldini
Luigi Naldini

11 February 2007 in Nature Cell Biology
Verified
Journal Article
Closed access
PDF file
ADArianna Dellavalle
Arianna Dellavalle
Maurilio SampaolesiMaurilio Sampaolesi
Maurilio Sampaolesi
RTRossana Tonlorenzi
Rossana Tonlorenzi
Enrico TagliaficoEnrico Tagliafico
Enrico Tagliafico
BSBenedetto Sacchetti
Benedetto Sacchetti
GCGiulio Cossu
Giulio Cossu

1 November 2006 in Nature
Verified
Journal Article
Closed access
PDF file
Maurilio SampaolesiMaurilio Sampaolesi
Maurilio Sampaolesi
SBStéphane Blot
Stéphane Blot
Giuseppe D'AntonaGiuseppe D'Antona
Giuseppe D'Antona
NGNicolas Granger
Nicolas Granger
RTRossana Tonlorenzi
Rossana Tonlorenzi
GCGiulio Cossu
Giulio Cossu

25 July 2003 in Science
Verified
Journal Article
Closed access
PDF file
Maurilio SampaolesiMaurilio Sampaolesi
Maurilio Sampaolesi
YTYvan Torrente
Yvan Torrente
AIAnna Innocenzi
Anna Innocenzi
RTRossana Tonlorenzi
Rossana Tonlorenzi
Giuseppe D'AntonaGiuseppe D'Antona
Giuseppe D'Antona
GCGiulio Cossu
Giulio Cossu
Preclinical or clinical trials for muscular dystrophies have met with modest success, mainly because of inefficient delivery of viral vectors or donor cells to dystrophic muscles. We report here that intra-arterial delivery of wild-type mesoangioblasts, a class of vessel-associated stem cells, corrects morphologically and functionally the dystrophic phenotype of virtually all downstream muscles in adult immunocompetent α-sarcoglycan (α-SG) null mice, a model organism for limb-girdle muscular dystrophy. When mesoangioblasts isolated from juvenile dystrophic mice and transduced with a lentiviral vector expressing α-SG were injected into the femoral artery of dystrophic mice, they reconstituted skeletal muscle in a manner similar to that seen in wild-type cells. The success of this protocol was mainly due to widespread distribution of donor stem cells through the capillary network, a distinct advantage of this strategy over previous approaches.

9 March 2007 in Cell Death & Differentiation
Verified
Journal Article
Closed access
RDR D'Aquino
R D'Aquino
AGA Graziano
A Graziano
Maurilio SampaolesiMaurilio Sampaolesi
Maurilio Sampaolesi
GLG Laino
G Laino
GPG Pirozzi
G Pirozzi
Gianpaolo PapaccioGianpaolo Papaccio
Gianpaolo Papaccio

26 January 2004 in Journal of Cell Biology
Verified
Journal Article
Open access
RPRoberta Palumbo
Roberta Palumbo
Maurilio SampaolesiMaurilio Sampaolesi
Maurilio Sampaolesi
FMFrancesco De Marchis
Francesco De Marchis
RTRossana Tonlorenzi
Rossana Tonlorenzi
SCSara Colombetti
Sara Colombetti
MBMarco E. Bianchi
Marco E. Bianchi
High mobility group box 1 (HMGB1) is an abundant chromatin protein that acts as a cytokine when released in the extracellular milieu by necrotic and inflammatory cells. Here, we show that extracellular HMGB1 and its receptor for advanced glycation end products (RAGE) induce both migration and proliferation of vessel-associated stem cells (mesoangioblasts), and thus may play a role in muscle tissue regeneration. In vitro, HMGB1 induces migration and proliferation of both adult and embryonic mesoangioblasts, and disrupts the barrier function of endothelial monolayers. In living mice, mesoangioblasts injected into the femoral artery migrate close to HMGB1-loaded heparin-Sepharose beads implanted in healthy muscle, but are unresponsive to control beads. Interestingly, α-sarcoglycan null dystrophic muscle contains elevated levels of HMGB1; however, mesoangioblasts migrate into dystrophic muscle even if their RAGE receptor is disabled. This implies that the HMGB1–RAGE interaction is sufficient, but not necessary, for mesoangioblast homing; a different pathway might coexist. Although the role of endogenous HMGB1 in the reconstruction of dystrophic muscle remains to be clarified, injected HMGB1 may be used to promote tissue regeneration.